Telix Pharmaceuticals Limited (NASDAQ:TLX), a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue.
• Telix Pharmaceuticals stock is testing lower boundaries. Why is TLX stock at lows?
Telix Hits FY 2025 Revenue Target
Australia-based Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, aligning with its upgraded guidance of $800-$820 million.
The company also noted a significant 46% year-over-year increase in the fourth quarter revenue, totaling around $208 million.
In addition, the Precision Medicine business generated approximately $161 million in revenue, reflecting a 4% quarter-over-quarter growth driven by the successful U.S. launch of Gozellix following its reimbursement approval by the Centers for Medicare and Medicaid Services (CMS) effective Oct. 1, 2025.
The company is also advancing its clinical studies, with international patients treated in the ProstACT Global Phase 3 study and the SOLACE Phase 1 study in the U.S.
Last week, Telix Pharmaceuticals dosed the first patient in the U.S. in the BiPASS Phase 3 trial to evaluate the …